PIK3CD and metastatic prostate carcinoma: A phase II trial of combining a second-generation AR antagonist and an inhibitor of AKT, a downstream component of the PI3K pathway, demonstrated significant improvement in radiographic progression-free survival (RPFS) for metastatic prostate cancer patients with tumors displaying loss of PTEN25.